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Abstract 
Inflammatory processes and metabolic alterations are supposed to substantially interact. Recently, cumulating reports 
describe a profound role of interleukin(IL)-22 in this relationship. IL-22 is a particular kind of immune mediator that is 
produced by certain lymphocyte populations and regulates the function of several tissue cells but not immune cells. 
So far, IL-22 was known to plays a fundamental role in the elimination of bacterial infections at border surfaces of the 
body and to protect tissues from damage. This research highlight article arranges the facts regarding the effects of 
IL-22 in the context of adiposity and metabolic alterations and postulates a new function of the immune system.
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The IL‑22/IL‑22R1 system
IL-22 is a small protein discovered in 2000 by the 
research group of Renauld [1]. The main producers of 
IL-22 are CD4+ effector/memory T-cells including 
T-helper(Th)1-, Th17-, and Th22-cells as well as group 
3 innate lymphoid cell (ILC3), the latter comprising 
natural killer cells, lymphoid tissue inducer like cells, 
and natural cytotoxicity receptor-positive ILCs [1]. 
The exact cellular sources of IL-22 in human diseases 
are often unknown and probably vary depending on 
the nature of the disorders. While the IL-22 secretion 
by Th-cells occurs following specific antigenic stimula-
tion supported by antigen-presenting cells, IL-22 pro-
duction by ILC3 is provoked by cytokines like IL-23, 
IL-1β, and tumor necrosis factor-α (TNF-α). This is 
important, because low inflammation is observed in 
people with adiposity and metabolic alterations and, 
via these inflammatory mediators, might cause per-
manent IL-22 production. IL-22 acts on cells situated 
near its producers. Additionally, it reaches the blood-
stream, where it is probably stabilized by IL-22-bind-
ing protein, and can therefore also influence cells far 
from its production site [1]. To mediate its biological 
effects, IL-22 uses a receptor complex composed of 
two different transmembrane chains: IL-22R1 and IL-
10R2 (Fig.  1) [1]. IL-10R2 additionally communicates 
the presence of IL-10, IL-26, IL-28, and IL-29 and is 
carried by many different types of cells. As we demon-
strated already in 2004, IL-22R1 determines the cellular 
sensitivity towards IL-22, is restricted to specific cell 
types, and is lacking on immune cells [2]. Accordingly, 
IL-22 represents a novel type of immune mediators 
that, although produced by immune cells, regulates 
the function of quite few tissue cells. The cells carry-
ing IL-22R1 comprise those of epithelial origins as well 
as fibroblast. Interestingly, IL-22R1 (in a complex with 
IL-20R2) is also used by the IL-22 “relatives” IL-20 and 
IL-24 (Fig.  1) [1]. Organs with strong IL-22R1 expres-
sion include the skin, liver, kidney, pancreas, and those 
of the respiratory and gastrointestinal systems [2]. 
IL-22 enhances the innate immunity of epithelia and 
plays a fundamental role in the elimination of bacterial 
infections at body surfaces [2]. Furthermore and as first 
demonstrated for hepatocytes/the liver by the research 
group of Bin Gao, IL-22 protects IL-22R1-carrying cells 
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from damage [3]. Such protection was later confirmed 
for pancreas and kidney. Although primarily protective, 
the very same effects might underlie the pathogenic 
role of IL-22 in some inflammatory diseases, as previ-
ously shown for psoriasis [2]. This is especially evident, 
when IL-22 effects are modulated and/or amplified by 
other cytokines such as IL-17 and/or TNF-α. In addi-
tion to all these data, recent reports announce a com-
pletely new kind of IL-22 action, which this article will 
focus on: as an intermediary between inflammation 
and metabolic alterations. In this context, there are 
two important questions: (1) Does endogenous IL-22 
modulate the development of adiposity and metabolic 
alterations? And (2), can exogenous IL-22 be used for 
the therapeutic treatment of adiposity and metabolic 
alterations?
Role of endogenous IL‑22 in the development 
of adiposity and metabolic alterations
The development of adiposity can be nicely investi-
gated in animal models generated by feeding of mice 
with high-fat diet (HFD) for several weeks. As inde-
pendently demonstrated by Wenjun Ouyang’s and 
Bin Gao’s groups, however, endogenous IL-22 does 
not play any role in the development of adiposity and 
metabolic alterations in these mice [4, 5]. In fact, there 
were no differences in body weight, glucose tolerance, 
and insulin resistance between IL-22-deficient mice 
and wild-type littermate controls. The reason for this 
lacking phenotype might lie in the very low levels of 
IL-22 (comparable to those in control mice) in young 
mice fed with high caloric diet and bred without other 
sources of inflammation. However, it seems that we 
cannot simply transfer these animal-based observa-
tions to the human situation [5]. The frequency of IL-
22-producing Th-cells in blood of patients suffering 
from type 2 diabetes mellitus (DM2) are higher than in 
control individuals [6]. Furthermore, IL-22-producing 
CD4+ T cells are enriched in adipose tissue of such 
patients [7, 8]. IL-1β, known for a long time as being 
strongly present in white fat tissue of adipose people, 
promotes IL-22 production by human adipose tissue 
CD4+ T cells [8]. Accordingly, blood concentration 
of IL-22 is elevated in DM2 patients [7]. The reason 
for this difference to mice might be that most human 
subjects with adiposity and metabolic alterations are 
older, their development of adiposity and metabolic 
alterations takes longer, and during this time these 
people sometimes have externally triggered inflamma-
tion (e.g. caused by banal infection) that might amplify 
the generation of lL-22-producing cells. We postulate 
that the presence of elevated IL-22 levels in adipose 
people is a counter-mechanism of the immune system 
to limit the development of adiposity and metabolic 
alterations (Fig.  2). This hypothesis contrasts the cur-
rent notion that inflammation generally worsens meta-
bolic alterations. Hints for such counter-mechanism 
by inflammatory mediators come from studies with 
IL-22R1-deficient mice. In fact, these animals were fat-
ter after already the first month of HFD ([4] and own 
observation) and developed higher levels of glucose 
intolerance and insulin resistance within 3 months 
[4]. This suggests that, already in quite young animals, 
endogenous IL-22R1 ligands—in this case other than 
IL-22 (i.e., IL-20 and/or IL-24)—are indeed able to 
counteract the development of adiposity (Fig. 2).
IL‑22 as therapeutic agent for adiposity 
and metabolic alterations
A recent report from Cell and Bioscience as well as 
three other manuscripts described that systemic appli-
cation of exogenous IL-22 is able to improve metabolic 
alterations in obese mice [4, 5, 9, 10]. The efficacy of 
such treatment seems to be dependent on both the dose 
of applied IL-22 and the previous duration of the meta-



















Fig. 1 IL-22, IL-20, and IL-24 and their receptor complexes. Binding of 
IL-22, IL-20, and IL-24 to their receptor complexes takes place in two 
steps: IL-22 initially binds to IL-22R1 while IL-20 and IL-24 primarily 
interact with IL-20R2 (a). The complete receptor complex for IL-22 
consists of IL-22R1 and IL-10R2. IL-20 and IL-24 can use two different 
receptor complexes: the IL-22R1/IL-20R2 complex and the IL-20R1/
IL-20R2 complex (b)
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intraperitoneal application of 2  μg/g mouse of IL-22Fc 
protein twice a week) markedly reduced body weight, 
decreased blood glucose levels under both fed and fast-
ing conditions and alleviated glucose intolerance and 
insulin resistance in mice that had been fed with HFD 
for 8  weeks [4]. In contrast, twice-a-week administra-
tion of 20  ng/g mouse of rmIL-22 did not affect body 
weight, fasting glucose levels, or insulin resistance in 
mice fed with HFD for previous 5  months [5]. Impor-
tantly, counteraction of metabolic alterations with 
elevated IL-22 levels seems to be based on numerous 
different effects of this cytokine (Fig.  3). First, IL-22Fc 
can raise serum levels of peptide YY, an anorexic gut 
hormone regulating food intake, and indeed minimizes 
food ingestion in young adipose mice [4]. Furthermore, 
IL-22 enhances the gut epithelial integrity and decreases 
the translocation of bacterial products like lipopoly-
saccharide (LPS) into blood serum. Thereby, it dimin-
ishes the LPS blood concentration, and thus indirectly 
reduces the activation of macrophages in adipose tissue 
[4]. The most prominent effects of IL-22 in this con-
text, however, are probable those on hepatocytes that 
result in the increase of liver functionality. Long-term 
treatment with rmIL-22 decreased the hepatic expres-
sion of enzymes for lipid synthesis like ATP citrate lyase 
(ACLY) as well as elongation of very long chain fatty 
acids like 6 (ELOVL6) and reduced hepatic triglyceride 
and cholesterol levels [9]. Furthermore, it decreased the 
expression of enzymes for gluconeogenesis like glucose-
6-phosphatase and phosphoenolpyruvate carboxyki-
nase (PEPCK) in hepatocytes and suppressed glucose 
production [5]. Additionally, high IL-22 levels were 
shown to act on adipocytes and elevate the expression 
of genes involved in triglyceride lipolysis [e.g. hormone-
sensitive lipase (LIPE) and patatin-like phospholipase 
domain-containing protein 2 (PNPLA2)] and fatty-acid 
β-oxidation (acyl-CoA oxidase 1, ACOX1) [4]. Accord-
ingly, the triglyceride content in white adipose tissue 
and serum was reduced in adipose mice treated with IL-
22Fc construct [4]. High IL-22 levels seem to increase 
the insulin sensitivity of the liver, muscle, and adipose 
tissue. Accordingly, IL-22 appears to increase glucose 
uptake in brown adipose tissue and heat production 
[4, 10]. Finally, IL-22 treatment leads to reduction of 
constitutive serum insulin concentration in obese mice 
and restores insulin production in response to glu-
cose provocation [4, 5, 10]. Whether the last fact is co-
determinated by a direct effect of IL-22 on pancreatic 
beta-cells is currently controversially discussed [5, 10]. 
While some reports do not observe IL-22R1 expres-
sion and IL-22-induced signal transduction in beta-cells 
[5], others postulated that IL-22 suppresses oxidative 
and endoplasmic reticulum stress in these cells and 
facilitates secretion of high-quality efficacious insulin 
[10]. Regardless of this controversy, it remains clear, 
that systemic application of exogenous IL-22 is able 
to improve metabolic alterations in adipose mice. It is 
currently impossible to estimate the extent we can use 
these very interesting discoveries for the development 
of the innovative treatment of human adiposity and 
disturbed metabolism. Not only because experiments 
with hepatocytes or adipocytes from obese subjects 
regarding IL-22 effects are missing so far. In princi-
pal, it appears quite easy to reach elevated IL-22 levels 
in humans: This can be achieved by application of this 
cytokine itself or by the activation of IL-22-inducing 
key signal transduction elements (e.g. aryl hydrocarbon 
receptor stimulation) by small molecules [as already 
shown for 6-formylindolo(3, 2-b)carbazole] [1]. Further 
studies need to clarify whether levels of IL-22 reached 
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Fig. 2 Role of endogenous IL-22 in the development of adiposity 
and metabolic alterations in mice and men. Adiposity can be induced 
by high caloric diet in mice and humans. Respective mouse models 
are based on massively forced fat intake of animals kept under 
pathogen-free conditions and usually involves very young mice (they 
are typically analyzed at an age of 20 % of their maximum age). Using 
such models, IL-22-deficient mice do not show a specific phenotype, 
although the activation of IL-22R1 by endogenous ligands seems 
to moderately limit the development of adiposity and metabolic 
alterations. In contrast to these mouse models, the development of 
adiposity and metabolic alterations in humans usually takes long 
time periods and leads to death within the second half of life. Impor-
tantly, banal infections or injury that occur over the extended time 
period might amplify the generation of IL-22-producing cells. We 
postulate that this endogenous IL-22 is a new counter-mechanism 
of the immune system to limit the development of adiposity and 
metabolic alterations
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concerns regarding the safety are rather limited due to 
the restricted target cell range of IL-22, especially its 
lacking immune modulation.
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